

Resource Summary Report

Generated by [NIF](#) on Sep 16, 2026

AN3-CA

RRID:CVCL_0028

Type: Cell Line

Proper Citation

RRID:CVCL_0028

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0028

Proper Citation: RRID:CVCL_0028

Description: Cell line AN3-CA is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Acanthosis nigricans

Defining Citation: [PMID:327080](#), [PMID:3518877](#), [PMID:6220172](#), [PMID:11668190](#), [PMID:14207855](#), [PMID:16957166](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20218740](#), [PMID:20944090](#), [PMID:22460905](#), [PMID:22710073](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: MD Anderson Cell Lines Project., Part of: Human Protein Atlas, Cell Atlas panel., Part of: ERK genetic alteration cell panel (ATCC TCP-1033)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AN3-CA

Synonyms: AN3_CA, AN3 CA, AN3 Ca, AN3CA, AN-3, AN3, Acanthosis Nigricans 3rd attempt-CArcinoma

Cross References: BTO:BTO_0001771, CLO:CLO_0001722, CLO:CLO_0037160, EFO:EFO_0002110, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783,

ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-111, BCRJ:0363, BioSample:SAMN03471092, BioSample:SAMN03473131, BioSample:SAMN03473336, BioSample:SAMN10988375, cancercellines:CVCL_0028, CCRID:4201HUM-CCTCC00127, CCTCC:GDC0127, Cell_Model_Passport:SIDM00901, ChEMBL-Cells:ChEMBL3308708, ChEMBL-Targets:ChEMBL1075392, CLS:300119, Cosmic:687550, Cosmic:699283, Cosmic:713473, Cosmic:713495, Cosmic:809134, Cosmic:846176, Cosmic:871551, Cosmic:889116, Cosmic:910781, Cosmic:980634, Cosmic:1007162, Cosmic:1057760, Cosmic:1066221, Cosmic:1070810, Cosmic:1102376, Cosmic:1105620, Cosmic:1177683, Cosmic:1223484, Cosmic:1434192, Cosmic:1576450, Cosmic:1622894, Cosmic:1696752, Cosmic:2030460, Cosmic:2646618, Cosmic-CLP:910781, DepMap:ACH-000940, DSMZ:ACC-267, DSMZCellDive:ACC-267, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910781, GEO:GSM374970, GEO:GSM375429, GEO:GSM827494, GEO:GSM886869, GEO:GSM887934, GEO:GSM1669600, GEO:GSM3161710, GEO:GSM3161711, GEO:GSM7701431, GEO:GSM7701432, IARC_TP53:21175, IGRhCellID:AN3CA, IZSLER:BS TCL 200, LiGeA:CCLE_574, LINCS_LDP:LCL-1499, PharmacoDB:AN3CA_63_2019, PRIDE:PXD030304, Progenetix:CVCL_0028, PubChem_Cell_line:CVCL_0028, TOKU-E:543, Wikidata:Q54749896

ID: CVCL_0028

Record Creation Time: 20220427T215219+0000

Record Last Update: 20260913T012128+0000

Ratings and Alerts

No rating or validation information has been found for AN3-CA.

No alerts have been found for AN3-CA.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. *International journal of biological macromolecules*, 369, 152809.

Carballo EV, et al. (2025) The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. *Clinical cancer*

research : an official journal of the American Association for Cancer Research, 31(24), 5294.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. *Cancer research communications*, 5(4), 719.

Satpathy S, et al. (2025) Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. *Cancer cell*, 43(9), 1731.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. *Molecular systems biology*, 21(8), 983.

Dong X, et al. (2024) ST6GALNAC1-mediated sialylation in uterine endometrial epithelium facilitates the epithelium-embryo attachment. *Journal of advanced research*.

Gong X, et al. (2024) Pyroptosis-associated genes and tumor immune response in endometrial cancer. *Discover oncology*, 15(1), 433.

Lv M, et al. (2024) TSLP enhances progesterin response in endometrial cancer via androgen receptor signal pathway. *British journal of cancer*, 130(4), 585.

Yang X, et al. (2023) PELP1 inhibition by SMIP34 reduces endometrial cancer progression via attenuation of ribosomal biogenesis. *Molecular oncology*.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. *Cancer discovery*, 13(9), 2012.

Patil A, et al. (2023) A disordered region controls cBAF activity via condensation and partner recruitment. *Cell*, 186(22), 4936.

O'Connor CM, et al. (2022) Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. *Cancer research*, 82(4), 721.

Wu Y, et al. (2021) MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. *Gynecologic oncology*, 163(1), 181.

Peck B, et al. (2021) 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. *Cancer research*, 81(4), 847.

Ohki Y, et al. (2019) Perturbation-Based Proteomic Correlation Profiling as a Target Deconvolution Methodology. *Cell chemical biology*, 26(1), 137.

Yasuhara T, et al. (2018) Human Rad52 Promotes XPG-Mediated R-loop Processing to Initiate Transcription-Associated Homologous Recombination Repair. *Cell*, 175(2), 558.